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increase but after five fractions of radiation. In BAT, the 
cytokine response was modest with significant increase 
of IL-8 after third dose of radiation. We found a positive 
correlation between baseline IL-8 and IL-6 microdialysis 
levels in tumor tissue and survival. Glucose metabolites 
or glycerol and glutamate did not change during radiation. 
In all tumors staining for macrophages was demonstrated. 
IL-6 was found in viable tumor cells while MCP-1 was 
demonstrated in macrophages or tumor matrix. Our find-
ings suggest that radiation induces a rapid enhancement 
of the prevailing inflammation in high-grade glioma tis-
sue. The microdialysis technique is feasible for this type 
of study and could be used to monitor metabolic changes 
after different interventions.
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Microdialysis · Inflammation
Introduction
Glioblastoma multiforme is the most common primary 
brain tumor and despite recent advances in the treatment 
the median time of survival is no >16  months after diagno-
sis [1]. During the last decade the importance of the tumor 
microenvironment of gliomas has gradually been acknowl-
edged [2–4]. The tumor microenvironment in the brain 
co tains an array of cells as microglia, reactive astrocytes, 
reactive neurons, endothelial cells, blood derived myeloid 
and lymphoid cells, and stromal cells as mesenchymal stro-
mal cells (MSC) and cancer associated fibroblast (CAF). 
Both immune and stromal cells induce an ongoing inflam-
mation within CNS tumors and the controversy has centered 
upo  whether thi  s in favor of the tumor or of the patient 
[5]. Accumulated data show that myeloid cells are the most 
Abstract The knowledge of respon e to rad ation i  th  
immuno-microenvironment of high grade gliomas is sparse. 
In vitro results have indicated an inflammatory response 
of myeloid cells after irradiation. Therefore, microdialysis 
was used to verify whether this is operative in tumor tissue 
and brain adjacent to tumor (BAT) after clinical radiother-
apy of patients with high gr de gli ma. Stereotactic biop-
sies and implantation of microdialysis catheters in tumor 
tissue and BAT were perform d in eleven patients with 
high-grade glioma. The patients were given daily radia-
tion fractions of 2–3.4 Gy. Microdialysis samp es were 
collected before radiotherapy and during the first five days 
of radiation. Cytokines, glucose metabolites, glutamate 
and glycerol were analyzed. Immunohistochemist y was 
performed to detect macrophages (CD68) and monocytes 
(CD163) as well as IL-6, IL-8 and MCP-1. A significant 
increase of IL-8, MCP-1 and MIP-1a were detected in 
tumor tissue already after the first dose of radiation and 
increased further during 5 days of radiation. IL-6 did also 
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correlation between metabolism and inflammation [19 , 20], 
we have additionally studied whether inflammation might 
have any relationship to the metabolic state of the tumor, to 
cell damage markers, or to clinical outcome.
Methods
Patients
Eleven patients were included in the study. All patients had 
a radiological suspicion of high-grade astrocytoma. The 
tumors were found not suitable for debulking surgery, and 
thus a stereotactic serial biopsy was performed for mor-
phological diagnosis. Ten of those patients had a histologi-
cally verified glioblastoma, whereas one of the patients had 
anaplastic astrocytoma (WHO grade III). There were eight 
men and three females with a mean age of 63 years (r ng  
50–81). The mean survival of the patients after diagnosis 
was 6.3months. This series of patients has previously been 
reported investigating the metabolomic response to radio-
therapy [21]. The local ethics committee in Umeå approved 
the study, and all patients gave their informed consent to 
participate in the study.
Surgery
Stereotactic serial biopsies were performed under general 
anesthesia and with the aid of a Leksell stereotactic frame 
(Elekta, Stockholm, Sweden). After mounting of the frame 
a stereotactic CT was performed for target calculations. The 
method used for stereotactic introduction of the microdi-
alysis catheters have been described in detail earlier [22]. 
Frozen sections confirmed the diagnosis before the micro-
dialysis catheters were stereotactically introduced. There 
were two catheters placed, one catheter in the biopsy target 
area, within the radiologically defined tumor, and a second 
catheter in brain adjacent to tumor (BAT), approximately 
10 mm outside the contrast-enhancing tumor. As a refer-
ence, one catheter was put in the abdominal subcutaneous 
tissue (SC). The accurate location of the intracranial cath-
eters was confirmed on postoperative CT performed for 
dose planning. The microdialysis equipment was fixed in 
the head dressing allowing the patient to move freely at the 
neurosurgical ward.
Postoperative care and radiotherapy
All the patients recovered and were monitored for the first 
24 h after surgery at the neurosurgical intensive care unit. 
The patients received betamethasone as perioperative rou-
tine and blood glucose was kept under 7 mmol/L. Eight 
patients were given conventional radiotherapy with daily 
common inflammatory cells in infiltrating human gliomas 
and thus of crucial importance for the microenvironment 
of the tumor [6]. Myeloid cells, as dendritic cells, microg-
lia and macrophages, can both boost or inhibit innate a d 
adaptive immune responses against tumors by releasing pro 
or anti-inflammatory cytokines [4, 7 , 8]. Apart from direct 
modulation of anti-tumor immunity, myeloid cells and other 
cells in the tumor microenvironment can promote tumor 
growth by tuning of angiogenesis, proliferation, metabolism 
and resistance against chemo- and radiotherapy [2, 9 , 10].
In this scenario one important issue is how the immune-
microenvironment of the CNS affects and i  affected by 
different treatment modalities. Radiation therapy is one 
of the pillars of malignant glioma treatment since several 
decades. The challenge of radiotherapy is to ablate the 
tumor without excessive damage to the surround g tissue. 
It is well known that following radiation exp sure there is 
both parenchymal and vascular damage leading to a radia-
tion induced cell death, involving not only tumor cells, but 
also oligodendrocytes, neur l progenitors and endothel al 
cells [11, 12]. Recent research has also emonstrated tha  
the effect of radiation is not only dependent on direct kill-
ing of tumor cells or tumor vessels but also by inflamma-
tory and immune secondary effects [13]. While mic ogl a 
and macrophages are more resistant to irradiation than other 
cells, they react by increasing production of reactive oxy-
gen species (ROS) and nitric oxide synthase (NOS). This 
together with release of damage associated molecular pat-
terns (DAMP) from damaged cells, induce inflammatory 
transcription factors as NFkB and RelB leading to release of 
inflammatory cytokines and chemokines. These can induce 
angiogenesis, edema and tissue damag , but will also re rui  
more inflammatory cells by chemotaxis and thus alter the 
immune-microenvironment [11, 14–16 ]. The change  in 
cellular composition at the site of radiation mainly result 
in an increased number of r active as rocytes, m rophages 
and microglia [13 , 17 ]. Accumulated evid nce f om experi-
mental in vitro and vivo studi s has prov ded indirec  evi-
dence that radiation of glio a cells or gli ma tissue leads 
to an increase in the secretion of inflammatory cytokines 
[11, 18].
A better understanding of the inflammatory response in 
glioma after radiotherapy would b  helpful in the develop-
ment and improvement of novel treatment strategies, such
as glioma immunotherapy. But, also in order to maximize 
tumor cell killing and avoid collateral damage to normal 
cells. Although circumstantial evidence h s indicated that 
radiotherapy induces the release of inflammatory media-
tors, no direct in situ proof of this has been presented. For 
this purpose we have investigated the effects of fracti nated 
radiotherapy on several cytokines involved in the immune 
and inflammatory system of glioblastoma by the use of 
microdialysis. As recent research has pointed to a close 
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Measurement of IFN-γ and IL-10 were not possible due to 
technical reasons. Samples were used in 1× or 2× dilution 
depending on available volume.
Immunohistochemistry
Tissues for histopathological studies were immersion-fixed 
in 4 % paraformaldehyde in 0.1 M Na phosphate, pH 7.4 
and then paraffin-embedded. From blocks of the stereotactic 
biopsies 4 µm thick sections were cut using a sliding micro-
tome and mounted on Superfrost™ slides (Thermo Fish r 
Scientific, Hägersten, Sweden). Slides were stained with 
Haematoxylin/Eosin and immunostained according to the 
manufacturer’s recommendations using the Benchmark Ultra 
(Ventana medical systems Inc, Illkirch, France). The sections 
for immunostaining were preincubated for 30 min in 3% 
H 2O 2 in methanol and then heated in 0.5 M citrate buffer (pH 
6.0) for 5 min in a microwave oven. The following primary 
antibodies were used: anti-GFAP (code Z 0334; Dakocyto-
mation, Glostrup, Denmark; 1:5000); anti-vimentin (catalog 
number 790–2917; Ventana medical systems; 1:1); anti-
IDH1(R132H) (clone H09; Dianova, Hamburg, Germany; 
1:50); anti-Ki-67 (clone 30-9; Ventana medical systems; 
1:50); anti-p53 (clone DO-7; Novocastra™, Newcastle-upon-
Tyne, England; 1:25); anti-EGFR (clone 3C6; Ventana 
medical systems; 1:100); anti-phosphohistone-H3 (catalog 
number 369A; Cell marque, Rocklin, CA, USA; 1:300); 
anti-human CD31 (clone JC70A; Dako, Glostrup, Denmark; 
1:10); anti-human CD68 (clone KP1; Dako; 1:2000; CC1 
pretreatment); anti-CD163 (clone 10D6; Novocastra; CC2 
pretreatment); anti-MCP1 (catalog number ab9669; Abcam, 
Cambridge, England; 1:100; CC2 pretreatment); anti-IL6 
(catalog number ab6672; Abcam; 1:200; CC1 pretreat-
ment); anti-IL8 (catalog number 17038-1-AP; Proteintech, 
Chicago, USA; 1:25; CC1 pretreatment). Micrographs were 
taken with a Olympus BX53 microscope equipped with a 
DP73 camera (Olympus, Hamburg, Germany) and using the 
CellSens dimension software (Olympus).
Statistical analyses
Statistical analyses were performed with Wilcoxon signed-
rank test and ANOVA using SPSS. The correlation coeffi-




There were no complications such as infection, haemor-
rhage, or increased cerebral edema in association with the 
2 Gy fractions up to 60 Gy. The volume incl d d the con-
trast enhanced tumor mass wit  a 2.5 cm margin. The irradi-
ation was started within 2–5 days after biopsy. Three elderly 
patients in a poor general condition were given a hypofrac-
tionated treatment with 3 Gy × 13 (two cases) or 3.4 Gy ×10 
(one case). The irradiation was given randomly at daytime 
between 8 am and 4.15 p i  all patient .
Microdialysis and analysis
The intracranial microdialysis catheters had 100-mm long 
shafts with an outer diamet r of 0.9 mm and a s m perm-
able membrane that was 10 mm long, while the subcuta-
neous reference catheters had 60 mm shafts with a 30 mm 
long membrane. The semiperm ble me brane was made
of polyamide and had a 100 kDa cut-off and an outer diam-
eter of 0.6 mm (CMA71; CMA Microdialysis, Stockholm, 
Sweden). To enable visualization of the catheters n CT, the 
catheters had a small gold ip. The catheters were connected 
to a microinfusion pump with a 2.5-mL syringe, set at a flow 
rate of 0.3 µL/min (CMA 106 or CMA 107; CMA Microdi-
alysis). All catheters were perfused with a Ring r solution 
(Perfusion fluid T1; CMA Microdialysis) mixed with Dex-
tran (30 g Dextran 60 1000/mL) to prevent microfiltration 
[23 ]. The microdialysis ran for at least 20 h before the first 
dose of radiation and continued during first 5 days of radia-
tion and then additionally for at east 20 h. The microdialy-
sis samples were collected n microvials eve y second hour, 
thereafter frozen and kept at −80 °C until analyzed.
Analysis of glucose metaboli s, glycero  and glutamate
For analysis of glucose metabolites, glycerol and glutamate, 
we selected samples, usually two, during a time span of 
4 h between midnight to six in the morning. These samples 
were thus fasting samples. All samples were analyzed using 
the CMA 600 analyzer (CMA Microdialysis). The CMA 
600 analyzer uses enzymatic reagents and colorimetric mea-
surements of the microdialysis samples [24]. A mean value 
of these samples were thereaf er calculated and used in the 
statistical analysis.
Analysis of cytokines
Cytokines were analyzed from sampl s collected the night 
before radiotherapy started, as baseline, and thereafter from 
samples collected during the same hours, after the first, 
third and fifth fractions of radiation. To analyze the cyto-
kine content of the microdialysis samples, a Cytokine Bead 
Array (CBA, BD, Stockholm) was performed according 
to the manufacturers’ recommendations. Flex-sets for the 
following human cytokines w used: IL-4, IL-6, IL-8, 
IL-10, TNF-α, IFN-γ, GM-CSF, MCP-1, MIP-1α, MIP-1β. 
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the specimens. This confirms the diagnosis of high grade 
tumors. The specimens showed an abundance of blood ves-
sels confirmed by the staining of the endothelial marker 
CD31 (Fig. 2A). Immunoreactivity for IDH1(R132H) was 
seen in four tumors, three of these being among the eight out 
of the eleven tumors that had a strong expression of EGFR.
In summary the immunohistochemistry together with the 
histopathological analysis conclude that all the patients had 
high grade (grade 3 and 4) astrocytic tumors.
To investigate the presence of infiltrating immunopotent 
cells such as macrophages and monocytes the specimens 
were stained for CD68 and CD163. All tumors showed cells 
that expressed CD163 strongly and all but one showed cells 
expressing CD68. The macrophages were more often than 
not seen in close approximation to blood vessels (Fig. 2B, C).
IL-6 was observed at high levels in all specimens. IL-6 
could mainly be seen in viable tissue surrounding the necrotic 
areas (Fig. 2D). Staining could be seen both intra- and extra-
cellular. When present, IL-8 and MCP-1 were, on the other 
hand, observed both in, and in areas surrounding, necrotic 
parts (Fig. 2E, F). IL-8 could not be detected by immunohis-
tochemistry in five patients while in the other patients it was 
seen in <25 % of the cells. On the other hand MCP-1 could 
be found in all patients. These cytokines were observed 
either in macrophages or in the extracellular matrix.
Correlations
We found a significant statistical correlation between 
baseline IL-8 and IL-6 microdialysis levels and survival 
(r2 = 0.28 and r2 = 0.13, respectively). However, there was 
no correlation between the increase following treatment in 
IL-6, IL-8 and MCP-1 and survival.
Discussion
There is strong evidence that immune and inflammatory reac-
tivity plays an important role in the regulation of both tumor 
progression and regression [2, 25]. Howev r, less is known 
about how different treatment modalities affect the immune 
and inflammatory-microenvironment in the CNS. Here we 
demonstrate an increase of IL-8, MCP-1 and MIP-1a intra-
tumorally already within 24 h after the first radiation dose. 
The increased levels of cytokines even progressed to higher 
levels during the first days of radiotherapy. Further, we could 
also observe a delayed increase in the levels of IL-6 and MIP-
1b. For IL-6 we could however observe an early decrease in 
BAT and SC tissue, while IL-8, MCP-1, MIP1-a and MIP1-
b showed an increase in BAT and SC tissue, although the 
increase was somewhat delayed compared to the increase in 
tumor tissue. MIP 1-b levels were also increased within 24 h 
after the first radiation dose in BAT. Taken in consideration 
microdialysis or the treatment. The pati nts were mobilized 
the day after surgery and could move freely within the neu-
rosurgical ward with the apparatus a tach d o a head cloth.
Cytokines
The cytokines that were reliably and constantly de e t d in 
the microdialysis samples and thus available for statistical 
analyses are presented in Fig. 1. An increase of IL-6 in the 
tumor could be observed after the fifth fraction of radia-
tion. In BAT and SC on the other hand, a decrease could 
be observed already after the first radiation fraction. IL-8 
levels in the tumor were significantly increased already 
within 24 h following the first given fractions of radiation, 
and increased further thereafter during the whole time of the 
radiation therapy. The IL-8 concentrations in BAT and SC 
increased with a delay compared to tumor tissue. MCP-1 
concentrations in tumor tissue did also significantly increase 
already after the first fraction and kept on increasing dur-
ing the time of radiotherapy. However, a significant increase 
could only be observed after the fifth fraction of radiation 
in SC tissue. The increase f MIP 1-a wa  muc  similar to 
MCP-1, with significant increase in tumor during the whole 
course of therapy, and only after the fifth fraction in SC tis-
sue. Finally, we could also observe a temporary significant 
increase in MIP 1-b levels in tumor after the third fraction 
of radiation. The concentration in SC was also increased but 
not until after the fifth fraction. We found no significant dif-
ference between the patients receiving tand rd dose, 2 Gy, 
and those receiving 3 and 3.4 Gy.
Glucose metabolites and markers
Baseline levels for glucose metabolites, glycerol and gluta-
mate were established. The figures are presented in Table 1. 
There were significant lower glucose and pyruvate levels 
within the tumor tissue compared to BAT. The levels of 
glutamate and lactate were on the other hand significantly 
higher in tumor tissue. Also the lactate-pyruvate rati  was 
significantly higher within the tumor tissue compared to 
BAT.
The levels of glucose metabolites were not significantly 
changed during the course of radio herapy. Neith r were
there any changes in the leve s of the potent al markers for 
tissue damage, glutamate and glycerol.
Immunohistochemistry
All tumors expressed GFAP (glial fibrillary acidic protein) 
and vimentin, markers for astr cytic tumo s. All patients 
except two had many cells exp s ing PHH3 (phosphohis-
tone-H3, a mitosis marker) and high Ki-67 labeling index, 
indicating a high proliferation w th a high mitotic rate in 
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The timing of radiation may be one factor that influence 
the levels of cytokines. However, we do not believe that the 
varying time points for irradiation was of significant impor-
tance since the results rather point towards an accumulation 
of the inflammatory cytokines over time during the 5 days.
that insertion of a microdialys s c thet r in rac rebral induces 
a decreasing release of inflammatory cytokines during 
1–4 days [26 , 27 ] our results strongly ndicate th t radiation 
per se induces an intra tumoral inflammatory reaction and an 
increased production and secretion of cytokines.
Fig. 1 Cytokines assessed by microdialysis in tumor tissue, brain 
adjacent to tumor (BAT) and abdominal subcutaneous tissue (SC) in 
11 patients with malignant glioma before irradiation and after the 1st, 
3rd, and 5th dose. The mean (SD) levels of IL-6, IL-8, MCP-1, MIP-1a 
and MIP-1b are expressed in pg/mL. Statistical analyses comparing the 
levels after irr d ation with base-line with Wilcoxon signed-rank test
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[39 ]. There is also an increased peripheral and local IL-6 
secretion in GBM patients compared with healthy controls 
[40, 41]. In GBM it has been linked to several features as 
invasiveness, angiogenesis, radioresistance and short sur-
vival [42–44].
IL-8 was first identified as a chemoattractant for granu-
locytic cells but also has pleiotrophic effects in tumors as 
direct or indirect induction of angiogenesis, invasiveness, 
recruitment of bone marrow cells, and maintenance of CSC 
in the perivascular niche [45–47 ]. IL-8 could be detected, 
by immunochemistry, in 50 % of the patients and was found 
mainly surrounding the necrotic areas of the tumor and 
around macrophages. However in microdialysis samples it 
was detected in all patients. The reason for this discrepancy 
could be that extra and intra cellular proteins as for other 
cytokines disguise the molecular epitope. The increase in 
IL-8 and MCP-1 was more rapid than that for IL-6 which 
could be explained by release of the latter from reacting 
tumor cells or infiltrating inflammatory cells recruited by 
the formers.
The immunohistochemical analysis showed a dense 
infiltration of myeloid cells. All tumors expressed CD163 
strongly and all but one expressed CD68. These results are 
in line with earlier reports where flow cytometric studies 
have showed that as much as one-third of the cells within 
gliomas could be microglia and macrophages [6 , 48, 49 ]. 
Both IL-8 and MCP-1, and to some extent also MIP1-a 
and MIP1-b, are potent chemoattractants for myeloid and 
granulocytic cells—and to some extent, lymphoid cells—
that will increase influx of inflammatory cells to the radiated 
The old concept that the effect of radiation on mamma-
lian cells depends solely on DNA damage has been revised 
by results demonstrating early release of ROS, NOS, 
growth factors and pro-inflammatory cytokines [12, 28]. 
The early NO and ROS production after radiation has been 
linked to rapid inflammatory changes in target cells but also 
to structural and inflammatory changes in bystander cells 
[29 –31]. As myeloid cells readily xpress iNOS they are the 
most potent producers of NO in the tumor microenviron-
ment after radiation. Interestingly, these re ctions have b en 
linked to both collateral damage f non-neoplas c issue
and to initiation of anti-tumor responses [11, 32 ]. Immu-
nohistochemical studies show that the early response after 
radiotherapy in high grade glioma is characterized by astro-
cytic gliosis, vascular proliferation, accumulation of acti-
vated microglia, and infiltration of macrophages [14–16 ]. 
The gradient of cytokines in our analysis definitely point at 
an intratumoral source of ytokin release although the BAT 
area also contributes. Secretomic d ta fr m cultured tumor 
and astrocytic cells clearly indicates that these are capable 
of producing various cytokines ncluding those highlighted 
in the present study [33 , 34]. Nevertheless accumulated da a 
and our immunohistochemistry results strongly imply that 
the overwhelming source of secreted inflammatory cyto-
kines emanate from myeloid cell, either infiltrating macro-
phages or resident microglia and that myeloid cel s are the 
drivers of other early features of reaction as astrocyte gliosis 
[5, 35 , 36 ].
IL-6 is a pleiotropic cytokine [37 , 38 ] wh ch is amplified 
and over-expressed in GBM cells both in viv and in vitro 
Fig. 2 Micrographs from glioblastoma tissue representative for the patients where cytokines were assessed by microdialysis. The sections were 
stained with CD31 (A), CD68 (B), CD 165 (C), IL-6 (D), IL-8 (E) and MCP-1 (F)
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tissue. The activated macrophages will secrete or induce the 
release of, proteolytic enzymes and additional inflamma-
tory cytokines [10, 50–52]. Although the significant longer 
survival in our patients with high expression of IL-8 indi-
cates that IL-8 could play a beneficial role in the CNS anti-
tumoral response the present materi l is to small to draw 
any conclusions.
In order to protect themselves against immune surveil-
lance neoplastic cells use several mechan sms to down-
regulate anti-tumor immunity. With ome xceptions 
inflammation has been shown to repress adaptive and some 
innate anti-tumor responses by the direct or indirect release 
of soluble factors as PGE2, TGF-b, NO or by inhibitory 
ligands as PD-L1, CTLA4 and TIGIT. By in irect means 
tumor cells can induce secretion of these by induction of 
monocytic and granulocytic myeloid cells. Despite some 
reports of enhanced adaptive immune responses, both 
IL-6 and IL-8 have overwhelmingly been associated with 
immune suppression through induction of regulatory T 
cells, myeloid derived suppressor cells [53] or direct effe ts 
[54–57 ]. Although none of the primary emblematic cyto-
kines associated with M (macrophage) or Th (T helper cells) 
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tern recorded more resembles M2 and Th2 subtypes. How-
ever, the delicate balance between immune po entiati n and 
immune suppression might depe d on the features or extent 
of inflammation as the therapeutic effects of low dose or 
non-fractioned irradiation has been shown to depend on 
immune reactivity [32 , 53 , 58]. To this end our results sh w 
that inflammatory cytokines are increasingly secreted after 
each fraction of radiotherapy.
Conclusion
Our findings suggest that irradiation induces a rapid 
enhancement of the prevailing inflammation in the tumor 
tissue of human GBMs. The microdialysis technique is fea-
sible for this type of study and could be used to, in vivo, 
monitor changes in cytokine secretion in high-grade glioma 
tissue after different interventions.
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